

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/212360 A1

(43) International Publication Date
28 October 2021 (28.10.2021)

(51) International Patent Classification:

A61K 45/06 (2006.01) *A61K 31/7048* (2006.01)
A61K 31/4155 (2006.01) *A61P 3/10* (2006.01)
A61K 31/381 (2006.01) *A61K 9/36* (2006.01)
A61K 31/351 (2006.01) *A61K 47/38* (2006.01)
A61K 31/382 (2006.01)

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

(21) International Application Number:

PCT/CN2020/086100

(22) International Filing Date:

22 April 2020 (22.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **HUA MEDICINE (SHANGHAI) LTD.**
[CN/CN]; 275 Ai Di Sheng Road, Pudong, Shanghai
201203 (CN).

(72) Inventors: **CHEN, Li**; No. 2 Chexin Highway, Building C-40, Songjiang, Shanghai 201612 (CN). **REN, Shuang**; 780 Cailun Road, Pudong, Shanghai 201203 (CN). **ZHANG, Jiayi**; 780 Cailun Road, Pudong, Shanghai 201203 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Suite B 1601A, 8 Xueqing Rd., Haidian, Beijing 100192 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR

(57) Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator and a sodium-glucose cotransporter-2 inhibitor.



WO 2021/212360 A1

**TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES
WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE
COTRANSPORTER-2 INHIBITOR**

FIELD

[0001] Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator (GKA) in combination with a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

BACKGROUND

[0002] Diabetes mellitus is a major health issue in the world. Nearly half a billion people are living with diabetes worldwide in 2019. *IDF Diabetes Atlas*; 9th ed.; International Diabetes Federation; 2019. Type 2 diabetes, *i.e.*, non-insulin dependent diabetes mellitus (NIDDM), accounts for more than 90% of diabetes worldwide. *Id.* Type 2 diabetes is a hyperglycemic, chronic, metabolic dysfunction resulting from an imbalance of blood glucose homeostasis in the human body caused by insulin secretion disorder and insulin resistance. The blood glucose balance of the human body is mainly coordinated by two hormones that control blood glucose, including insulin and glucagon. Glucagon-like peptide-1 (GLP-1) is involved in the regulation of insulin secretion. GLP-1 is also a therapeutic drug for diabetes that plays an important role in the blood glucose balance in human body. Insulin and GLP-1 analogues have become important drugs for the treatment of diabetes.

[0003] Glucokinase (GK) plays a central role in stabilizing the blood glucose balance in human body. GK as a glucose sensor in glucose homeostasis, regulates the secretion of glucagon, insulin, and GLP-1 stimulated by glucose. GK is mainly distributed in the liver, where it rapidly converts glucose into hepatic glycogen for storage in response to elevated blood glucose and meanwhile lowers the glucose level in the blood. Defect of glucokinase causes impaired glucose tolerance (IGT) and type 2 diabetes. However, there is currently no GKAs approved for clinical use.

[0004] Because of the progressive failure of beta cells, type-2 diabetes is an evolving disease that requires progressive treatment intensification over time in order to control glucose adequately. Scheen, *Expert Opin. Pharmacother.* 2017, 18, 503-515. Treatment resistance is common and a major challenge in managing type-2 diabetes. *Id.*; Stone *et al.*,

Diabetes Care 2013, 36, 2628-2638. A large number of type-2 diabetes patients have poor glycemic control despite oral therapy combining metformin, a sulfonylurea, and another glucose-lowering agent. Scheen, *Expert Opin. Pharmacother.* 2017, 18, 503-515. Therefore, there is a clinical need to be met in the field of a diabetes, particularly in treating a treatment-resistant diabetes.

SUMMARY OF THE DISCLOSURE

[0005] Provided herein is a method of treating an untreated or treatment-resistant diabetes, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a GKA and (ii) a therapeutically effective amount of an SGLT2 inhibitor.

[0006] Also provided herein is a method of treating an untreated or treatment-resistant diabetes, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a GKA and (ii) a therapeutically effective amount of an SGLT2 inhibitor; wherein the GKA is (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and the SGLT2 inhibitor is empagliflozin, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

DETAILED DESCRIPTION

[0007] To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.

[0008] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, biochemistry, biology, and pharmacology described herein are those well known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0009] The term “subject” refers to an animal, including, but not limited to, a primate (*e.g.*, human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms

“subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.

[0010] The terms “treat,” “treating,” and “treatment” are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.

[0011] The terms “prevent,” “preventing,” and “prevention” are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition.

[0012] The terms “alleviate” and “alleviating” refer to easing or reducing one or more symptoms (*e.g.*, pain) of a disorder, disease, or condition. The terms can also refer to reducing adverse effects associated with an active ingredient. Sometimes, the beneficial effects that a subject derives from a prophylactic or therapeutic agent do not result in a cure of the disorder, disease, or condition.

[0013] The term “therapeutically effective amount” or “effective amount” is meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated. The term “therapeutically effective amount” or “effective amount” also refers to the amount of a compound that is sufficient to elicit a biological or medical response of a biological molecule (*e.g.*, a protein, enzyme, RNA, or DNA), cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.

[0014] The term “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of a subject (*e.g.*, a human or an animal) without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable

benefit/risk ratio. *See, e.g., Remington: The Science and Practice of Pharmacy*, 22nd ed.; Allen Ed.: Philadelphia, PA, 2012; *Handbook of Pharmaceutical Excipients*, 8th ed.; Sheskey *et al.*, Eds.; The Pharmaceutical Press: 2017; *Handbook of Pharmaceutical Additives*, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; *Pharmaceutical Preformulation and Formulation*, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.

[0015] The term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.

[0016] In certain embodiments, “optically active” and “enantiomerically active” refer to a collection of molecules, which has an enantiomeric excess of no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, an optically active compound comprises about 95% or more of one enantiomer and about 5% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 98% or more of one enantiomer and about 2% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 99% or more of one enantiomer and about 1% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.

[0017] In describing an optically active compound, the prefixes *R* and *S* are used to denote the absolute configuration of the compound about its chiral center(s). The (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound. The (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise. The (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise. However, the

sign of optical rotation, (+) and (-), is not related to the absolute configuration of the compound, *R* and *S*.

[0018] The term “isotopically enriched” refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), tritium (^3H), carbon-11 (^{11}C), carbon-12 (^{12}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), fluorine-18 (^{18}F), phosphorus-31 (^{31}P), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-35 (^{35}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-127 (^{127}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). In certain embodiments, an isotopically enriched compound is in a stable form, that is, non-radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), carbon-12 (^{12}C), carbon-13 (^{13}C), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), phosphorus-31 (^{31}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), and iodine-127 (^{127}I). In certain embodiments, an isotopically enriched compound is in an unstable form, that is, radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, tritium (^3H), carbon-11 (^{11}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), fluorine-18 (^{18}F), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-35 (^{35}S), chlorine-36 (^{36}Cl), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). It will be understood that, in a compound as provided herein, any hydrogen can be ^2H , as example, or any carbon can be ^{13}C , as example, or any nitrogen can be ^{15}N , as example, or any oxygen can be ^{18}O , as example, where feasible according to the judgment of one of ordinary skill in the art.

[0019] The term “isotopic enrichment” refers to the percentage of incorporation of a less prevalent isotope (*e.g.*, D for deuterium or hydrogen-2) of an element at a given position in a molecule in the place of a more prevalent isotope (*e.g.*, ^1H for protium or hydrogen-1) of the

element. As used herein, when an atom at a particular position in a molecule is designated as a particular less prevalent isotope, it is understood that the abundance of that isotope at that position is substantially greater than its natural abundance.

[0020] The term “isotopic enrichment factor” refers the ratio between the isotopic abundance in an isotopically enriched compound and the natural abundance of a specific isotope.

[0021] The term “deuterium enrichment” refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1% at a given position means that 1% of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156% on average, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156% on average. As used herein, when a particular position in an isotopically enriched compound is designated as having deuterium, it is understood that the abundance of deuterium at that position in the compound is substantially greater than its natural abundance (0.0156%).

[0022] The terms “substantially pure” and “substantially homogeneous” mean sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods used by one of ordinary skill in the art, including, but not limited to, thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry (MS); or sufficiently pure such that further purification would not detectably alter the physical, chemical, biological, and/or pharmacological properties, such as enzymatic and biological activities, of the substance. In certain embodiments, “substantially pure” or “substantially homogeneous” refers to a collection of molecules, wherein at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% by weight of the molecules are a single compound, including a single enantiomer, a racemic mixture, or a mixture of enantiomers, as determined by standard analytical methods. As used herein, when an atom at a particular position in an isotopically enriched molecule is designated as a particular less prevalent isotope, a molecule that contains other than the designated isotope at the specified position is an impurity with respect to the isotopically enriched compound. Thus, for a deuterated compound that has an atom at

[0027] In another embodiment, the GKA is one disclosed in U.S. Pat. No. 7,741,327 B2 or 9,388,168 B2, the disclosure of each of which is incorporated herein by reference in its entirety.

[0028] In certain embodiments, the GKA is deuterium-enriched. In certain embodiments, the GKA is carbon-13 enriched. In certain embodiments, the GKA is carbon-14 enriched. In certain embodiments, the GKA contains one or more less prevalent isotopes for other elements, including, but not limited to, ^{15}N for nitrogen; ^{17}O or ^{18}O for oxygen, and ^{33}S , ^{34}S , or ^{36}S for sulfur.

[0029] In certain embodiments, the GKA has an isotopic enrichment factor of no less than about 5, no less than about 10, no less than about 20, no less than about 30, no less than about 40, no less than about 50, no less than about 60, no less than about 70, no less than about 80, no less than about 90, no less than about 100, no less than about 200, no less than about 500, no less than about 1,000, no less than about 2,000, no less than about 5,000, or no less than about 10,000. In any events, however, an isotopic enrichment factor for a specified isotope is no greater than the maximum isotopic enrichment factor for the specified isotope, which is the isotopic enrichment factor when the GKA at a given position is 100% enriched with the specified isotope. Thus, the maximum isotopic enrichment factor is different for different isotopes. The maximum isotopic enrichment factor is 6,410 for deuterium and 90 for carbon-13.

[0030] In certain embodiments, the GKA has a deuterium enrichment factor of no less than about 64 (about 1% deuterium enrichment), no less than about 130 (about 2% deuterium enrichment), no less than about 320 (about 5% deuterium enrichment), no less than about 640 (about 10% deuterium enrichment), no less than about 1,300 (about 20% deuterium enrichment), no less than about 3,200 (about 50% deuterium enrichment), no less than about 4,800 (about 75% deuterium enrichment), no less than about 5,130 (about 80% deuterium enrichment), no less than about 5,450 (about 85% deuterium enrichment), no less than about 5,770 (about 90% deuterium enrichment), no less than about 6,090 (about 95% deuterium enrichment), no less than about 6,220 (about 97% deuterium enrichment), no less than about 6,280 (about 98% deuterium enrichment), no less than about 6,350 (about 99% deuterium enrichment), or no less than about 6,380 (about 99.5% deuterium enrichment). The deuterium enrichment can be determined using conventional analytical methods known to

one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0031] In certain embodiments, the GKA has a carbon-13 enrichment factor of no less than about 1.8 (about 2% carbon-13 enrichment), no less than about 4.5 (about 5% carbon-13 enrichment), no less than about 9 (about 10% carbon-13 enrichment), no less than about 18 (about 20% carbon-13 enrichment), no less than about 45 (about 50% carbon-13 enrichment), no less than about 68 (about 75% carbon-13 enrichment), no less than about 72 (about 80% carbon-13 enrichment), no less than about 77 (about 85% carbon-13 enrichment), no less than about 81 (about 90% carbon-13 enrichment), no less than about 86 (about 95% carbon-13 enrichment), no less than about 87 (about 97% carbon-13 enrichment), no less than about 88 (about 98% carbon-13 enrichment), no less than about 89 (about 99% carbon-13 enrichment), or no less than about 90 (about 99.5% carbon-13 enrichment). The carbon-13 enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0032] In certain embodiments, at least one of the atoms of the GKA as specified as isotopically enriched has isotopic enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the GKA as specified as isotopically enriched have isotopic enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In any events, the isotopic enrichment of the isotopically enriched atom of the GKA is no less than the natural abundance of the isotope specified.

[0033] In certain embodiments, at least one of the atoms of the GKA as specified as deuterium-enriched, has deuterium enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the GKA as specified as deuterium-enriched, have deuterium enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than

about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[0034] In certain embodiments, at least one of the atoms of the GKA as specified as ¹³C-enriched, has carbon-13 enrichment of no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the GKA as specified as ¹³C-enriched, have carbon-13 enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[0035] In certain embodiments, the GKA is isolated or purified. In certain embodiments, the GKA has a purity of at least about 50%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% by weight.

[0036] The GKA is intended to encompass all possible stereoisomers, unless a particular stereochemistry is specified. Where the GKA contains an alkenyl group, the GKA may exist as one or mixture of geometric *cis/trans* (or *Z/E*) isomers. Where structural isomers are interconvertible, the GKA may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the GKA that contains, for example, an imino, keto, or oxime group; or so-called valence tautomerism in the GKA that contain an aromatic moiety. It follows that a single GKA may exhibit more than one type of isomerism.

[0037] The GKA can be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, *e.g.*, a racemic mixture of two enantiomers; or a mixture of two or more diastereomers. As such, one of ordinary skill in the art will recognize that administration of a GKA in its (*R*) form is equivalent, for GKAs that undergo epimerization *in vivo*, to administration of the GKA in its (*S*) form. Conventional techniques for the preparation/isolation of individual enantiomers include synthesis from a suitable optically pure precursor, asymmetric synthesis from achiral starting materials, or resolution of an enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

[0038] When the GKA contains an acidic or basic moiety, it can also be provided as a pharmaceutically acceptable salt. See, Berge *et al.*, *J. Pharm. Sci.* 1977, 66, 1-19; *Handbook of Pharmaceutical Salts: Properties, Selection, and Use*, 2nd ed.; Stahl and Wermuth Eds.; Wiley-VCH and VHCA, Zurich, 2011.

[0039] Suitable acids for use in the preparation of pharmaceutically acceptable salts of the GKA include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1*S*)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α -oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, (\pm)-DL-lactic acid, lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid, malonic acid, (\pm)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, undecylenic acid, and valeric acid.

[0040] Suitable bases for use in the preparation of pharmaceutically acceptable salts of the GKA, including, but not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, or sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, *N*-methyl-glucamine, hydrabamine, 1*H*-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline, isoquinoline, triethanolamine, trimethylamine,

triethylamine, *N*-methyl-*D*-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.

[0041] The GKA may also be provided as a prodrug, which is a functional derivative of the GKA and is readily convertible into the parent GKA *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent GKA. They may, for instance, be bioavailable by oral administration whereas the parent GKA is not. The prodrug may also have enhanced solubility in pharmaceutical compositions over the parent GKA. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.

[0042] In certain embodiments, the GKA is formulated as a pharmaceutical composition comprising the GKA and a pharmaceutically acceptable excipient.

[0043] The GKA pharmaceutical composition can be formulated in various dosage forms, including, but not limited to, dosage forms for oral, parenteral, and topical administration. The GKA pharmaceutical composition can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. *See, e.g., Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Delivery Technology*, 2nd ed.; Rathbone *et al.*, Eds.; Drugs and the Pharmaceutical Sciences 184; CRC Press: Boca Raton, FL, 2008.

[0044] In one embodiment, a GKA pharmaceutical composition is formulated in a dosage form for oral administration. In another embodiment, a GKA pharmaceutical composition is formulated in a dosage form for parenteral administration. In yet another embodiment, a GKA pharmaceutical composition is formulated in a dosage form for intravenous administration. In yet another embodiment, a GKA pharmaceutical composition is formulated in a dosage form for intramuscular administration. In yet another embodiment, a GKA pharmaceutical composition is formulated in a dosage form for subcutaneous administration. In still another embodiment, a GKA pharmaceutical composition is formulated in a dosage form for topical administration.

[0045] A GKA pharmaceutical composition provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to

physically discrete a unit suitable for administration to a subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) (*e.g.*, the GKA described herein) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical excipient(s). Examples of a unit-dosage form include, but are not limited to, an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in a segregated unit-dosage form. Examples of a multiple-dosage form include, are not limited to, a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[0046] The GKA pharmaceutical composition can be administered at once or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the subject being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the subject's need and the professional judgment of the person administering or supervising the administration of the GKA pharmaceutical composition.

[0047] In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 1 to about 1,000, from about 5 to about 500, from about 10 to about 250, from about 10 to about 150, or from about 20 to about 100 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 1 to about 1,000 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 5 to about 500 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 10 to about 250 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 10 to about 150 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount ranging from about 25 to about 100 mg per

unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount of about 10, about 20, about 25, about 30, about 40, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, or about 150 mg per unit (*e.g.*, a tablet). In certain embodiments, the GKA pharmaceutical composition contains a GKA described herein (*e.g.*, dorzagliatin) in an amount of about 25, about 50, about 75, or about 100 mg per unit (*e.g.*, a tablet).

[0048] In one embodiment, the GKA pharmaceutical composition (hereinafter, “dorzagliatin formulation”) described herein comprises (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[0049] In another embodiment, the dorzagliatin formulation is one disclosed in U.S. Pat. Appl. Pub. No. 2019/0328713 A1; the disclosure of which is incorporated herein by reference in its entirety.

[0050] In certain embodiments, the dorzagliatin formulation is formulated for oral administration. In certain embodiments, the dorzagliatin formulation is formulated as capsule. In certain embodiments, the dorzagliatin formulation is formulated as a tablet. In certain embodiments, the tablet is film-coated.

[0051] In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 1 to about 1,000, from about 5 to about 500, from about 10 to about 250, from about 10 to about 150, or from about 20 to about 100 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 1 to about 1,000 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 5 to about 500 mg per unit (*e.g.*, a tablet). In certain embodiments, the

dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 10 to about 250 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 10 to about 150 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount ranging from about 20 to about 100 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount of about 10, about 25, about 30, about 40, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, or about 150 mg per unit (*e.g.*, a tablet). In certain embodiments, the dorzagliatin formulation contains (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide in an amount of about 25, about 50, about 75, or about 100 mg per unit (*e.g.*, a tablet).

[0052] In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 0.1 to about 50, from about 0.2 to about 20, from about 0.5 to about 10, or from about 1 to about 5 mg/kg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 0.1 to about 50 mg/kg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 0.2 to about 20 mg/kg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 0.5 to about 10 mg/kg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 1 to about 5 mg/kg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is about 0.5, about 0.7, about 1, about 1.2, about 1.5, about 1.7, about 2, about 2.2, about 2.5, about 2.7, about 3, about 3.5, about 4, about 4.5, or about 5 mg/kg per day.

[0053] In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 5 to about 1,000, from about 10 to about 500, or from about 20 to about 200 mg per day. In certain embodiments, the therapeutically effective

amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 5 to about 1,000 mg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 10 to about 500 mg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is ranging from about 20 to about 200 mg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is about 20, about 40, about 60, about 80, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, or about 200 mg per day. In certain embodiments, the therapeutically effective amount of the GKA (*e.g.*, dorzagliatin) is about 25, about 50, or about 75 mg per day.

[0054] In certain embodiments, the GKA (*e.g.*, dorzagliatin) is administered once daily (QD), or divided into multiple daily doses such as twice daily (BID), and three times daily (TID). In certain embodiments, the GKA (*e.g.*, dorzagliatin) is administered once daily (QD). In certain embodiments, the GKA (*e.g.*, dorzagliatin) is administered twice daily (BID). In certain embodiments, the GKA (*e.g.*, dorzagliatin) is administered three times daily (TID).


[0055] In certain embodiments, the GKA is administered under fasted conditions. In certain embodiments, the GKA is administered without a food. In certain embodiments, the GKA is administered at least about 10, about 20, about 30, about 40, or about 60 min before a meal. In certain embodiments, the GKA is administered at least 1, 2, or 3 hours after a meal.

[0056] It will be understood, however, that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors including the activity of the specific GKA (*e.g.*, dorzagliatin), the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0057] In one embodiment, the SGLT2 inhibitor is bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, phlorizin, remogliflozin, sergliflozin, sotagliflozin, or tofogliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In another embodiment, the SGLT2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, or tofogliflozin; or a tautomer, a


mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In yet another embodiment, the SGLT2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In still another embodiment, the SGLT2 inhibitor is empagliflozin, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0058] In one embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-(4-chloro-3-{[4-(2-cyclopropoxyethoxy)phenyl]methyl}phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol (also known as bexagliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is bexagliflozin.

[0059] In another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol (also known as canagliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is canagliflozin.

[0060] In yet another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol (2*S*,3*R*,4*R*,5*S*,6*R*)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol (also known as dapagliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is dapagliflozin.

[0061] In yet another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-[4-chloro-3-({4-[(3*S*)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol (also known as empagliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is empagliflozin.

[0062] In yet another embodiment, the SGLT2 inhibitor is (1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (also known as ertugliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is ertugliflozin.

[0063] In yet another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol (also known as ipragliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is ipragliflozin.

[0064] In yet another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol (also known as luseogliflozin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is luseogliflozin.

[0065] In yet another embodiment, the SGLT2 inhibitor is 1-[2,4-dihydroxy-6-[(2*S*,3*R*,4*S*,5*S*,6*R*)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-(4-hydroxyphenyl)propan-1-one (also known as phlorizin):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is phlorizin.

[0066] In yet another embodiment, the SGLT2 inhibitor is ethyl [(2*R*,3*S*,4*S*,5*R*,6*S*)-3,4,5-trihydroxy-6-{[5-methyl-1-(propan-2-yl)-4-{[4-(propan-2-yloxy)phenyl]methyl}-1*H*-pyrazol-3-yl]oxy}oxan-2-yl]methyl carbonate (also known as remogliflozin etabonate):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is remogliflozin.

[0067] In yet another embodiment, the SGLT2 inhibitor is ethyl (((2*R*,3*S*,4*S*,5*R*,6*S*)-3,4,5-trihydroxy-6-(2-(4-methoxybenzyl)phenoxy)tetrahydro-2*H*-pyran-2-yl)methyl) carbonate (also known as sergliflozin etabonate):




or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is sergliflozin etabonate.

[0068] In yet another embodiment, the SGLT2 inhibitor is (2*S*,3*R*,4*R*,5*S*,6*R*)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(methylsulfanyl)oxane-3,4,5-triol (also known as sotagliflozin):



or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is sotagliflozin.

[0069] In still another embodiment, the SGLT2 inhibitor is (1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-3H-spiro[2-benzofuran-1,2'-oxane]-3',4',5'-triol (also known as tofogliflozin):



or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the SGLT2 inhibitor is tofogliflozin.

[0070] In certain embodiments, the SGLT2 inhibitor is deuterium-enriched. In certain embodiments, the SGLT2 inhibitor is carbon-13 enriched. In certain embodiments, the SGLT2 inhibitor is carbon-14 enriched. In certain embodiments, the SGLT2 inhibitor contains one or more less prevalent isotopes for other elements, including, but not limited to, ^{15}N for nitrogen; ^{17}O or ^{18}O for oxygen, and ^{33}S , ^{34}S , or ^{36}S for sulfur.

[0071] In certain embodiments, the SGLT2 inhibitor has an isotopic enrichment factor of no less than about 5, no less than about 10, no less than about 20, no less than about 30, no less than about 40, no less than about 50, no less than about 60, no less than about 70, no less than about 80, no less than about 90, no less than about 100, no less than about 200, no less than about 500, no less than about 1,000, no less than about 2,000, no less than about 5,000, or no less than about 10,000. In any events, however, an isotopic enrichment factor for a specified isotope is no greater than the maximum isotopic enrichment factor for the specified isotope, which is the isotopic enrichment factor when the SGLT2 inhibitor at a given position is 100% enriched with the specified isotope. Thus, the maximum isotopic enrichment factor is different for different isotopes. The maximum isotopic enrichment factor is 6410 for deuterium and 90 for carbon-13.

[0072] In certain embodiments, the SGLT2 inhibitor has a deuterium enrichment factor of no less than about 64 (about 1% deuterium enrichment), no less than about 130 (about 2% deuterium enrichment), no less than about 320 (about 5% deuterium enrichment), no less than about 640 (about 10% deuterium enrichment), no less than about 1,300 (about 20% deuterium enrichment), no less than about 3,200 (about 50% deuterium enrichment), no less than about 4,800 (about 75% deuterium enrichment), no less than about 5,130 (about 80%

deuterium enrichment), no less than about 5,450 (about 85% deuterium enrichment), no less than about 5,770 (about 90% deuterium enrichment), no less than about 6,090 (about 95% deuterium enrichment), no less than about 6,220 (about 97% deuterium enrichment), no less than about 6,280 (about 98% deuterium enrichment), no less than about 6,350 (about 99% deuterium enrichment), or no less than about 6,380 (about 99.5% deuterium enrichment). The deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0073] In certain embodiments, the SGLT2 inhibitor has a carbon-13 enrichment factor of no less than about 1.8 (about 2% carbon-13 enrichment), no less than about 4.5 (about 5% carbon-13 enrichment), no less than about 9 (about 10% carbon-13 enrichment), no less than about 18 (about 20% carbon-13 enrichment), no less than about 45 (about 50% carbon-13 enrichment), no less than about 68 (about 75% carbon-13 enrichment), no less than about 72 (about 80% carbon-13 enrichment), no less than about 77 (about 85% carbon-13 enrichment), no less than about 81 (about 90% carbon-13 enrichment), no less than about 86 (about 95% carbon-13 enrichment), no less than about 87 (about 97% carbon-13 enrichment), no less than about 88 (about 98% carbon-13 enrichment), no less than about 89 (about 99% carbon-13 enrichment), or no less than about 90 (about 99.5% carbon-13 enrichment). The carbon-13 enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0074] In certain embodiments, at least one of the atoms of the SGLT2 inhibitor as specified as isotopically enriched has isotopic enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the SGLT2 inhibitor as specified as isotopically enriched have isotopic enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In any events, the isotopic enrichment of the isotopically enriched atom of the SGLT2 inhibitor is no less than the natural abundance of the isotope specified.

[0075] In certain embodiments, at least one of the atoms of the SGLT2 inhibitor as specified as deuterium-enriched has deuterium enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the SGLT2 inhibitor as specified as deuterium-enriched have deuterium enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[0076] In certain embodiments, at least one of the atoms of the SGLT2 inhibitor as specified as ¹³C-enriched has carbon-13 enrichment of no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%. In certain embodiments, the atoms of the SGLT2 inhibitor as specified as ¹³C-enriched have carbon-13 enrichment of no less than about 1%, no less than about 2%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[0077] In certain embodiments, the SGLT2 inhibitor is isolated or purified. In certain embodiments, the SGLT2 inhibitor has a purity of at least about 50%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% by weight.

[0078] The SGLT2 inhibitors described herein are intended to encompass all possible stereoisomers, unless a particular stereochemistry is specified. Where the SGLT2 inhibitor contains an alkenyl group, the SGLT2 inhibitor may exist as one or mixture of geometric *cis/trans* (or *Z/E*) isomers. Where structural isomers are interconvertible, the SGLT2 inhibitor may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the SGLT2 inhibitor that contains, for example, an imino, keto, or oxime group; or so-called valence tautomerism in the SGLT2 inhibitor that contain an aromatic moiety. It follows that a single SGLT2 inhibitor may exhibit more than one type of isomerism.

[0079] The SGLT2 inhibitor can be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, *e.g.*, a racemic mixture of two enantiomers; or a mixture of two or more diastereomers. As such, one of ordinary skill in the art will recognize that administration of a SGLT2 inhibitor in its (*R*) form is equivalent, for SGLT2 inhibitors that undergo epimerization *in vivo*, to administration of the SGLT2 inhibitor in its (*S*) form. Conventional techniques for the preparation/isolation of individual enantiomers include synthesis from a suitable optically pure precursor, asymmetric synthesis from achiral starting materials, or resolution of an enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

[0080] When the SGLT2 inhibitor contains an acidic or basic moiety, it can also be provided as a pharmaceutically acceptable salt. *See*, Berge *et al.*, *J. Pharm. Sci.* 1977, 66, 1-19; *Handbook of Pharmaceutical Salts: Properties, Selection, and Use*, 2nd ed.; Stahl and Wermuth Eds.; Wiley-VCH and VHCA, Zurich, 2011.

[0081] Suitable acids for use in the preparation of pharmaceutically acceptable salts of the SGLT2 inhibitor include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1*S*)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α -oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, (\pm)-DL-lactic acid, lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid, malonic acid, (\pm)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, undecylenic acid, and valeric acid.

[0082] Suitable bases for use in the preparation of pharmaceutically acceptable salts of the SGLT2 inhibitor, including, but not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, or sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, *N*-methyl-glucamine, hydrabamine, 1*H*-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline, isoquinoline, triethanolamine, trimethylamine, triethylamine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.

[0083] The SGLT2 inhibitor may also be provided as a prodrug, which is a functional derivative of a SGLT2 inhibitor, for example, remogliflozin etabonate or sergliflozin etabonate and is readily convertible into the parent SGLT2 inhibitor *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent SGLT2 inhibitor. They may, for instance, be bioavailable by oral administration whereas the parent SGLT2 inhibitor is not. The prodrug may also have enhanced solubility in pharmaceutical compositions over the parent SGLT2 inhibitor. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.

[0084] In certain embodiments, canagliflozin or a pharmaceutically acceptable salt is formulated as described in the package insert for INVOKANA®. In certain embodiments, dapagliflozin or a pharmaceutically acceptable salt is formulated as described in the package insert for FARXIGA®. In certain embodiments, empagliflozin or a pharmaceutically acceptable salt is formulated as described in the package insert for JARDIANCE®. In certain embodiments, ertugliflozin or a pharmaceutically acceptable salt is formulated as described in the package insert for STEGLATRO®.

[0085] In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 1 to about 1,000, from about 1 to about 500, from about 1 to about 250, from about 1 to about 100, from about 2 to about 50, or from about 5 to about 50 mg per day mg per day. In certain embodiments, the therapeutically

effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 1 to about 1,000 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 1 to about 500 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 1 to about 250 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 1 to about 100 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 2 to about 50 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is ranging from about 5 to about 50 mg per day. In certain embodiments, the therapeutically effective amount of the SGLT2 inhibitor (*e.g.*, empagliflozin) is about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 mg per day.

[0086] In certain embodiments, the SGLT2 inhibitor (*e.g.*, empagliflozin) is administered under fasted conditions. In certain embodiments, the SGLT2 inhibitor (*e.g.*, empagliflozin) is administered without a food. In certain embodiments, the SGLT2 inhibitor (*e.g.*, empagliflozin) is administered at least about 10, about 20, about 30, about 40, or about 60 min before a meal. In certain embodiments, the SGLT2 inhibitor (*e.g.*, empagliflozin) is administered at least 1, 2, or 3 hours after a meal.

[0087] The GKA can be administered prior to (*e.g.*, 5 min, 15 min, 50 min, 65 min, 1 h, 2 h, 6 h, 12 h, 26 h, 68 h, 72 h, or 96 h before), concomitantly with, or subsequent to (*e.g.*, 5 min, 15 min, 50 min, 65 min, 1 h, 2 h, 6 h, 12 h, 26 h, 68 h, 72 h, or 96 h after) the administration of the SGLT2 inhibitor to the subject. In one embodiment, the GKA is administered concurrently with the SGLT2 inhibitor. In another embodiment, the GKA is administered separately with the SGLT2 inhibitor. In yet another embodiment, the GKA is administered sequentially with the SGLT2 inhibitor. In yet another embodiment, the GKA is administered before the SGLT2 inhibitor. In yet another embodiment, the GKA is administered after the SGLT2 inhibitor.

[0088] In one embodiment, the diabetes is an untreated or treatment-resistant type 1 diabetes. In another embodiment, the diabetes is an untreated or treatment-resistant type 2 diabetes.

[0089] In certain embodiments, the diabetes is a diabetes with persistent hyperglycemia. In certain embodiments, the diabetes is a diabetes with a glyated hemoglobin level (HbA1c) of no less than about 7%. In certain embodiments, the diabetes is a diabetes with an HbA1c of no less than about 8%. In certain embodiments, the diabetes is a diabetes with an HbA1c of no less than about 9%. In certain embodiments, the is a diabetes with an HbA1c of no less than about 10%.

[0090] In certain embodiments, the diabetes is a diabetes with an HbA1c of no less than about 64 mmol/mol. In certain embodiments, the diabetes is a diabetes with an HbA1c of no less than about 75 mmol/mol. In certain embodiments, the diabetes is a diabetes with an HbA1c of no less than about 86 mmol/mol.

[0091] In certain embodiments, the treatment-resistant diabetes is a diabetes with persistent hyperglycemia despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 7% despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 8% despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 9% despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 10% despite pharmacological treatment with at least three oral glucose-lowering medications.

[0092] In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 64 mmol/mol despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 75 mmol/mol despite pharmacological treatment with at least three oral glucose-lowering medications. In certain embodiments, the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 86 mmol/mol despite pharmacological treatment with at least three oral glucose-lowering medications.

[0093] In certain embodiments, the treatment-resistant diabetes is a diabetes with persistent poorly-controlled diabetes despite standard care with three oral glucose-lowering medications.

[0094] In one embodiment, the treatment-resistant diabetes is resistant to metformin, a meglitinide, a dipeptidyl peptidase 4 (DPP-4) inhibitor, an SGLT2 inhibitor, an insulin, a sulfonylurea, a thiazolidinedione, a glucagon-like peptide-1 (GLP-1) agonist, or a combination thereof.

[0095] In one embodiment, the treatment-resistant diabetes is resistant to a DPP-4 inhibitor. In another embodiment, the treatment-resistant diabetes is resistant to an SGLT-2 inhibitor. In yet another embodiment, the treatment-resistant diabetes is resistant to metformin. In yet another embodiment, the treatment-resistant diabetes is resistant to a DPP-4 inhibitor and an SGLT-2 inhibitor. In yet another embodiment, the treatment-resistant diabetes is resistant to a DPP-4 inhibitor and metformin. In yet another embodiment, the treatment-resistant diabetes is resistant to an SGLT-2 inhibitor and metformin. In still another embodiment, the treatment-resistant diabetes is resistant to a DPP-4 inhibitor, an SGLT-2 inhibitor, and metformin.

[0096] In certain embodiments, the treatment-resistant diabetes is resistant to a DPP-4 inhibitor. In certain embodiments, the treatment-resistant diabetes is resistant to alogliptin, anagliptin, dutogliptin, evogliptin, gemigliptin, gosogliptin, linagliptin, omarigliptin, saxagliptin, sitagliptin, teneligliptin, trelagliptin, or vildagliptin. In certain embodiments, the treatment-resistant diabetes is resistant to alogliptin, anagliptin, evogliptin, gemigliptin, gosogliptin, linagliptin, omarigliptin, saxagliptin, sitagliptin, teneligliptin, trelagliptin, or vildagliptin. In certain embodiments, the treatment-resistant diabetes is resistant to alogliptin, linagliptin, saxagliptin, or sitagliptin.

[0097] In certain embodiments, the treatment-resistant diabetes is resistant to an SGLT2 inhibitor. In certain embodiments, the treatment-resistant diabetes is resistant to bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, phlorizin, remogliflozin, sergliflozin, sotagliflozin, or tofogliflozin. In certain embodiments, the treatment-resistant diabetes is resistant to canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, or tofogliflozin. In certain embodiments, the

treatment-resistant diabetes is resistant to canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin.

[0098] In certain embodiments, the treatment-resistant diabetes is resistant to a GLP-1 receptor agonist. In certain embodiments, the treatment-resistant diabetes is resistant to albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, or semaglutide.

[0099] In certain embodiments, the treatment-resistant diabetes is resistant to an insulin. In certain embodiments, the treatment-resistant diabetes is resistant to a fast-acting insulin, a short-acting insulin, an intermediate-acting insulin, a long-acting insulin, or an ultra-long acting insulin.

[00100] In certain embodiments, the treatment-resistant diabetes is resistant to a meglitinide. In certain embodiments, the treatment-resistant diabetes is resistant to nateglinide or repaglinide.

[00101] In certain embodiments, the treatment-resistant diabetes is resistant to a sulfonylurea. In certain embodiments, the treatment-resistant diabetes is resistant to chlorpropamide, gliclazide, glimepiride, or tolazamide.

[00102] In certain embodiments, the treatment-resistant diabetes is resistant to a thiazolidinedione. In certain embodiments, the treatment-resistant diabetes is resistant to balaglitazone, ciglitazone, darglitazone, englitazone, lobeglitazone, netoglitazone, pioglitazone, rivoglitazone, rosiglitazone, or troglitazone. In certain embodiments, the treatment-resistant diabetes is resistant to lobeglitazone, rosiglitazone, or pioglitazone.

[00103] In certain embodiments, the subject with a treatment-resistant diabetes fails a monotherapy. In certain embodiments, the subject with a treatment-resistant diabetes fails a dual-agent therapy.

[00104] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

[00105] A method provided herein encompasses treating a subject regardless of subject's age, although some diseases are more common in certain age groups.

[00106] In one embodiment, provided herein is a method of treating a treatment-resistant diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of dorzagliatin and a therapeutically effective amount of empagliflozin. In certain embodiments, the therapeutically effective amount of dorzagliatin is about 150 mg per day and the therapeutically effective amount of empagliflozin is from about 10 to about 50 mg per day. In certain embodiments, the therapeutically effective amount of dorzagliatin is about 150 mg per day and the therapeutically effective amount of empagliflozin is about 25 mg per day. In certain embodiments, dorzagliatin is administered in an amount of 75 mg twice daily and empagliflozin is administered in an amount of about 25 mg daily. In certain embodiments, the therapeutically effective amount of dorzagliatin is about 25, about 50, or about 75 mg per day and the therapeutically effective amount of empagliflozin is about 25 mg per day.

[00107] The disclosure will be further understood by the following non-limiting examples.

EXAMPLES

[00108] As used herein, the symbols and conventions used in these processes, schemes and examples, regardless of whether a particular abbreviation is specifically defined, are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society, the Journal of Medicinal Chemistry, or the Journal of Biological Chemistry. Specifically, but without limitation, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); dL (deciliters); mL (microliters); mM (millimolar); mol (moles); mmol (millimoles); h (hour or hours); and min (minutes).

Example 1

Phase 1, open-label, sequential, multiple-dose, drug-drug interaction (DDI) study of dorzagliatin and empagliflozin in subjects with type-2 diabetes mellitus (T2DM)

[00109] This phase I study accessed the pharmacokinetic interaction between dorzagliatin and empagliflozin in T2DM subjects. This study also evaluated the safety and tolerability of dorzagliatin with simultaneous administration of empagliflozin in T2DM subjects. Moreover, this study accessed the pharmacodynamic responses of serum glucose, insulin, C-peptide, plasma glucagon, urinary glucose excretion following dorzagliatin, empagliflozin, or simultaneous administration of dorzagliatin and empagliflozin in T2DM subjects.

[00110] Sixteen eligible subjects were enrolled and 15 of them completed the study. Study drugs were administered according to the dosing scheme provided in Table 1.

TABLE 1: Treatment Scheme

Day	Empagliflozin	Dorzagliatin	PK Sample Collection
1-5	25 mg (QD) for 5 days	-	Day 5: Empagliflozin alone
6-10	25 mg (QD) for 5 days	75 mg (BID) for 4 days Morning dose only on Day 10	Day 10: Empagliflozin + dorzagliatin
11-15	-	75 mg (BID) for 4 days Morning dose only on Day 15	Day 15: Dorzagliatin alone

[00111] All subjects received: (i) empagliflozin (25 mg, QD) on Days 1-5; and empagliflozin was taken 60 min prior to meals (except on Day 5, when it was administered 30 min before glucose intake); (ii) empagliflozin (25 mg, QD) and dorzagliatin (75 mg, BID) on Days 6-10 (only the morning dose on Day 10); and empagliflozin and dorzagliatin were taken 60 min prior to meals (except on Day 10, when they were administered 30 min before glucose intake); or (iii) dorzagliatin 75 mg BID on Days 11-15 (only the morning dose on Day 15); and dorzagliatin was taken 60 min prior to meals (except on Day 15, when it was administered 30 min before glucose intake).

[00112] Eligible subjects had a minimum 12-day run-in period prior to admission to a clinical research center (CRC), during which time they self-administered empagliflozin (25 mg, QD) each morning. Empagliflozin, a glucometer, and a diary were dispensed to each subject by the CRC. Subjects were advised to monitor their blood glucose levels and report changes in health status to the CRC. Subjects completed the diary to record empagliflozin doses taken each day and the results of the blood glucose monitoring. On Day -14, the CRC trained the subjects in how to use the glucometer and fill out the diary. The subjects then tested their blood glucose levels and self-administered the Day -14 dose of empagliflozin on-site and were asked to record both in the diary immediately. A telephone call was placed to each subject at approximately Day -8 during the run-in period to assess general health and collect adverse event (AE) information. The subjects returned the glucometers to the CRC on Day -2.

[00113] Following completion of the run-in period, eligible subjects were admitted to the CRC on Day -2, had a total of 18 overnight stays, and were discharged after End-of-Study procedures were completed on Day 17 or at early termination.

[00114] On Days 5, 10 and 15, a 75-gram glucose solution (oral glucose tolerance test, OGTT) was administered 30 min post-drug administration. No breakfast was provided.

[00115] Blood samples for the determination of dorzagliatin and empagliflozin concentrations and corresponding pharmacokinetic (PK) analysis were collected at the following time points on Days 5, 10 and 15: pre-dose (within 30 min prior to drug dosing) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h post-dose.

[00116] Pharmacodynamic (PD) responses, *i.e.*, serum levels of glucose, insulin and C-peptide and plasma levels of glucagon, were evaluated on Days 5, 10 and 15: pre-dose (within 60 min prior to glucose intake) and at 0.5, 1, 1.5, 2, 2.5, 3 and 4 h post-glucose intake. Urine was collected for urinary glucose excretion on Days 5, 10 and 15: pre-dose (for bladder emptying only, no pre-dose glucose measurement), and over a series of intervals (0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h and 12-24 h post-dose).

[00117] Safety assessments included monitoring of AEs, blood glucose *via* glucometer readings, vital signs (blood pressure, pulse rate, respiratory rate, and oral temperature), clinical laboratory findings, 12-lead ECGs, and PE findings including body weight at various time points during the study.

[00118] Vital signs were performed at screening, on Day -1, on Days 1-15 within 60 minutes prior to each study drug dose, and on Day 17. A staff used the glucometer on the subjects, three times a day, within 60 min before each meal or glucose intake and after study drug dosing when applicable (no measurement on Day 17). Clinical laboratory evaluations were performed at screening, on Day -1, Days 5, 10 and 15 and at the End-of-Study on Day 17. A resting 12-lead ECG was completed at screening, Day -1, and 2 h post-dose on Day 5, Day 10 and Day 15, and at the End-of-Study on Day 17. PEs were conducted at screening, Day -1, and at the End-of-Study on Day 17.

[00119] Eligible subjects for the study were subjects diagnosed with T2DM at least 3 months prior to screening and were currently taking a stable dose of the following therapy with no changes in the dosage for at least 4 weeks prior to screening: (i) ≥ 1000 mg per day of metformin; (ii) a DPP-4 inhibitor; (iii) an SGLT2 inhibitor; (iv) metformin plus a DPP-4 inhibitor; or (v) metformin plus an SGLT2 inhibitor. Subjects must agree to change their current therapy to empagliflozin (25 mg, QD) for at least 14 days prior to dosing on Day 1. Additional inclusion criteria for the eligible subjects included (i) male and/or female subjects

between the ages of 30 and 65 years; (ii) with a body mass index (BMI) of 19 to 38 kg/m² at screening; (iii) fasting C-peptide test result > 0.3 nmol/L (> 0.90 ng/mL); (iv) HbA1c \geq 7% and \leq 10.5%

[00120] The study excluded those with (i) fasting blood glucose at screening or Day -1 \leq 110 or \geq 270 mg/dL; (ii) type 1 diabetes mellitus, or latent autoimmune diabetes in adults; diabetic neuropathy, retinopathy or nephropathy; (iii) reported incidence of severe hypoglycemia within 3 months prior to screening and/or within 3 months prior to dosing on Day 1; (iv) known contraindications to empagliflozin; (v) clinically significant gastrointestinal disorders; (vi) history or symptoms of clinically significant cardiovascular diseases; (vii) reported history of liver diseases; (viii) reported history of clinically significant renal diseases; (ix) estimated glomerular filtration rate (eGFR) \leq 60 mL/min/1.73 m²; (x) acute or chronic metabolic acidosis, including diabetic ketoacidosis; (xi) known or suspected malignancy; (xii) any reported hypersensitivity or intolerance to empagliflozin; (xiii) antidiabetic treatment with insulin, sulfonylureas, thiazolidinediones or GLP-1 agonist within 3 months prior to screening; (xiv) systolic blood pressure < 90 or > 160 mmHg or diastolic blood pressure < 60 or > 100 mmHg at screening; (xv) uncontrolled hypertriglyceridemia > 500 mg/dL; (xvi) female is breast-feeding or planning to become pregnant; or (xvii) reported history of donation or acute loss of blood during the 90 days prior to screening.

[00121] Dorzagliatin was provided as a film-coated tablet in 75 mg strength for oral administration 60 min prior to a meal. Empagliflozin was provided as JARDIANCE® (25 mg) film-coated tablets for oral administration 60 min prior to a meal. The total duration of participation in the study for each subject was about 45 days (up to 14-day screening period, 12-day run-in period, and 19-day in-clinic period).

[00122] The plasma concentration-time data for dorzagliatin and empagliflozin were analyzed using non-compartmental methods to calculate PK parameters. Empagliflozin did not have a significant effect on dorzagliatin PK parameters based on the analysis of plasma dorzagliatin C_{max} and AUC_{0-24h}. Least squares geometric means for C_{max} were 889 and 856 for dorzagliatin in combination with empagliflozin and dorzagliatin alone, respectively, with a percent ratio of geometric means (GMR) of 104% (90% CI: 90, 119). Least squares geometric means for AUC_{0-24h} were 6,490 and 6,510 for dorzagliatin in combination with empagliflozin and dorzagliatin alone, respectively, with a percent GMR of 99.7% (90% CI: 95, 104). A lack of a significant drug-drug interaction for the effect of empagliflozin on

dorzagliatin PK parameters was supported by the percent GMR 90% CI for dorzagliatin C_{max} and AUC_{0-24h} being fully contained within the 80.00 to 125.00% boundaries.

[00123] Dorzagliatin did not have a significant effect on empagliflozin PK parameters based on the analysis of plasma empagliflozin C_{max} and AUC_{0-24h}. Least squares geometric means for C_{max} were 387 and 393 for empagliflozin in combination with dorzagliatin and empagliflozin alone, respectively, with a percent GMR of 98.4% (90% CI: 84, 115). Least squares geometric means for AUC_{0-24h} were 3,030 and 3,108 for empagliflozin in combination with dorzagliatin and empagliflozin alone, respectively, with a percent GMR of 97.5% (90% CI: 94, 101). A lack of a significant drug-drug interaction for the effect of dorzagliatin on empagliflozin PK parameters is supported by the percent GMR 90% CI for empagliflozin C_{max} and AUC_{0-24h} being fully contained within the 80.00 to 125.00% boundaries.

[00124] Following the oral glucose tolerance test (OGTT), combination treatment of empagliflozin and dorzagliatin achieved significantly better glucose lowering effect than administration of either empagliflozin or dorzagliatin treatment alone, based on the resulted glucose PD parameters (baseline corrected AUEC_{0-4h}, CE_{max}, and CE_{av}) as summarized in Table 2.

TABLE 2: Glucose Responses

Parameter	Statistic	Empagliflozin	Empagliflozin + Dorzagliatin	Dorzagliatin
CE _{max} (mg/dL)	n	16	15	15
	Mean (SD)	199 (51)**	145 (40)	163 (38)*
AUEC _{0-4h} (h·mg/dL)	n	16	15	15
	Mean (SD)	452 (165)**	279 (105)	364 (121) [#]
CE _{av} (mg/dL)	n	16	15	15
	Mean (SD)	113 (41)**	70 (26)	91 (30)*

*P < 0.01; **P < 0.0001; [#]P < 0.05

[00125] As summarized in Table 3, mean baseline corrected insulin levels following combination treatment of empagliflozin and dorzagliatin were higher than either empagliflozin or dorzagliatin monotherapy.

TABLE 3: Insulin Responses

Parameter	Statistic	Empagliflozin	Empagliflozin + Dorzagliatin	Dorzagliatin
CE _{max} (mg/dL)	n	16	15	15
	Mean (SD)	46 (24) #	67 (38)	56 (27)
AUEC _{0-4h} (h·mg/dL)	n	16	15	15
	Mean (SD)	91 (39) #	127 (68)	110 (52)
CE _{av} (mg/dL)	n	16	15	15
	Mean (SD)	23 (9.7) #	32 (17)	28 (13)

#P < 0.05

[00126] As summarized in Table 4 and similar to insulin, baseline corrected AUEC_{0-4h}, CE_{max}, and CE_{av} of C-peptide following combination administration of empagliflozin and dorzagliatin were higher than those for administration of either empagliflozin or dorzagliatin monotherapy.

TABLE 4: C-peptide Responses

Parameter	Statistic	Empagliflozin	Empagliflozin + Dorzagliatin	Dorzagliatin
CE _{max} (mg/dL)	n	16	14	15
	Mean (SD)	4.7 (2.0) *	7.0 (4.0)	5.5 (2.5) #
AUEC _{0-4h} (h·mg/dL)	n	16	14	15
	Mean (SD)	11 (4.7) *	16 (9.0)	13 (6.0)
CE _{av} (mg/dL)	n	16	14	15
	Mean (SD)	2.7 (1.2) *	4.0 (2.3)	3.2 (1.5) #

*P < 0.01; #P < 0.05

* * * * *

[00127] The examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments, and are not intended to limit the scope of what is disclosed herein. Modifications that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference.

What is claimed is:

1. A method of treating an untreated or treatment-resistant diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of a glucokinase activator and a therapeutically effective amount of a sodium-glucose cotransporter-2 inhibitor.
2. The method of claim 1, wherein the glucokinase activator is (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide, or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
3. The method of claim 1 or 2, wherein the glucokinase activator is (*S*)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)-*N*-(1-((*R*)-2,3-dihydroxypropyl)-1*H*-pyrazol-3-yl)-4-methylpentanamide.
4. The method of any one of claims 1 to 3, wherein the therapeutically effective amount of the glucokinase activator is ranging from about 0.1 to about 50 mg/kg per day.
5. The method of any one of claims 1 to 4, wherein the therapeutically effective amount of the glucokinase activator is ranging from about 5 to about 1,000 mg per day.
6. The method of any one of claims 1 to 5, wherein the therapeutically effective amount of the glucokinase activator is about 150 mg per day.
7. The method of any one of claims 1 to 6, wherein the glucokinase activator is administered orally.
8. The method of any one of claims 1 to 7, wherein the glucokinase activator is administered orally as a tablet.
9. The method of any one of claims 1 to 8, wherein the glucokinase activator is administered twice a day.
10. The method of any one of claims 1 to 9, wherein the sodium-glucose cotransporter-2 inhibitor is bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, phlorizin, remogliflozin, sergliflozin, sotagliflozin, or tofogliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

11. The method of any one of claims 1 to 10, wherein the sodium-glucose cotransporter-2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, or tofogliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

12. The method of any one of claims 1 to 11, wherein the sodium-glucose cotransporter-2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

13. The method of any one of claims 1 to 12, wherein the sodium-glucose cotransporter-2 inhibitor is empagliflozin; or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

14. The method of any one of claims 1 to 13, wherein the sodium-glucose cotransporter-2 inhibitor is empagliflozin.

15. The method of any one of claims 1 to 14, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is ranging from about 1 to about 1,000 mg per day.

16. The method of any one of claims 1 to 15, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is ranging from about 5 to about 50 mg per day.

17. The method of any one of claims 1 to 16, wherein the therapeutically effective amount of the sodium-glucose cotransporter-2 inhibitor is about 25 mg per day.

18. The method of any one of claims 1 to 17, wherein the sodium-glucose cotransporter-2 inhibitor is administered orally.

19. The method of any one of claims 1 to 18, wherein the sodium-glucose cotransporter-2 inhibitor is administered once a day.

20. The method of any one of claims 1 to 19, wherein the treatment-resistant diabetes is a treatment-resistant type-2 diabetes.

21. The method of any one of claims 1 to 20, wherein the treatment-resistant diabetes is a diabetes with persistent hyperglycemia.

22. The method of any one of claims 1 to 21, wherein the treatment-resistant diabetes is a diabetes with persistent hyperglycemia despite pharmacological treatment with at least three oral glucose-lowering medications.

23. The method of any one of claims 1 to 22, wherein the treatment-resistant diabetes is a diabetes with persistent poorly-controlled diabetes despite standard care with three oral glucose-lowering medications.

24. The method of any one of claims 1 to 23, wherein the treatment-resistant diabetes is a diabetes with a glycated hemoglobin level (HbA1c) of no less than about 7%.

25. The method of any one of claims 1 to 24, wherein the treatment-resistant diabetes is a diabetes with an HbA1c of no less than about 64 mmol/mol.

26. The method of any one of claims 1 to 25, wherein the treatment-resistant diabetes is resistant to metformin, a meglitinide, a dipeptidyl peptidase 4 (DPP-4) inhibitor, an SGLT2 inhibitor, an insulin, a sulfonylurea, a thiazolidinedione, a glucagon-like peptide-1 (GLP-1) agonist, or a combination thereof.

27. The method of any one of claims 1 to 26, wherein the treatment-resistant diabetes is resistant to metformin, a DPP-4 inhibitor, an SGLT2 inhibitor, or a combination thereof.

28. The method of any one of claims 1 to 27, wherein the treatment-resistant diabetes is resistant to metformin.

29. The method of any one of claims 1 to 28, wherein the treatment-resistant diabetes is resistant to a DPP-4 inhibitor.

30. The method of any one of claims 1 to 29, wherein the treatment-resistant diabetes is resistant to an SGLT2 inhibitor.

31. The method of any one of claims 1 to 30, wherein the subject is a human.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2020/086100

A. CLASSIFICATION OF SUBJECT MATTER		
A61K 45/06(2006.01)i; A61K 31/4155(2006.01)i; A61K 31/381(2006.01)i; A61K 31/351(2006.01)i; A61K 31/382(2006.01)i; A61K 31/7048(2006.01)i; A61P 3/10(2006.01)i; A61K 9/36(2006.01)i; A61K 47/38(2006.01)i		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K; A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CNABS;CNTXT;DWPI;SIPOABS;WOTXT;USTXT;EPTXT;CNKI;ISI Web of Science;STN: glucokinase activator; sodium-glucose cotransporter-2 inhibitor; bexagliflozin; canagliflozin; dapagliflozin; empagliflozin; ertugliflozin; ipragliflozin; luseogliflozin; phlorizin; remogliflozin; sergliflozin; sotagliflozin; tofogliflozin; GKA; SGLT2; diabetes; untreated; treatment-resistant; HUA MEDICINE; CHEN,Li; REN,Shuang; ZHANG, Jiayi; 1191995-00-2		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CN 110548148 A (HUA MEDICINE SHANGHAI LTD.) 10 December 2019 (2019-12-10) claims 1, 3, 7, 14, 81, paragraph[0058]	1-31
A	WO 2018030879 A1 (NOVMETAPHARMA CO., LTD. et al.) 15 February 2018 (2018-02-15) the whole document	1-31
A	US 2015315176 A1 (HUA MEDICINE) 05 November 2015 (2015-11-05) the whole document	1-31
A	WO 2012006398 A2 (BHV PHARMA, INC.) 12 January 2012 (2012-01-12) the whole document	1-31
A	WO 2019228362 A1 (HUA MEDICINE SHANGHAI LTD.) 05 December 2019 (2019-12-05) the whole document	1-31
A	US 2009264445 A1 (BERTHEL Steven Joseph et al.) 22 October 2009 (2009-10-22) the whole document	1-31
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 06 January 2021		Date of mailing of the international search report 20 January 2021
Name and mailing address of the ISA/CN National Intellectual Property Administration, PRC 6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing 100088 China		Authorized officer WU,Likun
Facsimile No. (86-10)62019451		Telephone No. 86-(10)-53961868

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **1-31**
because they relate to subject matter not required to be searched by this Authority, namely:
 - [1] Claims 1-31 direct to a method of treating an untreated or treatment-resistant
 - [2] diabetes, they do not meet the criteria set out in PCT Rules 39.1(iv). The search report has been carried out and based on the use of a therapeutically effective
 - [3] amount of a glucokinase activator and a therapeutically effective amount of a
 - [4] sodium-glucose cotransporter-2 inhibitor for the manufacturing of a medicament for the treatment of an untreated or treatment-resistant diabetes.

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2020/086100

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)				
CN	110548148	A	10 December 2019	TW	202003502	A	16 January 2020				
				TW	202003464	A	16 January 2020				
				CN	110548147	A	10 December 2019				
				TW	202003499	A	16 January 2020				
				CN	110548149	A	10 December 2019				
				CN	110548027	A	10 December 2019				
				TW	202003501	A	16 January 2020				
				CN	110548146	A	10 December 2019				
				WO	2019228367	A1	05 December 2019				
				WO	2019228366	A1	05 December 2019				
				TW	202003498	A	16 January 2020				
				WO	2019228365	A1	05 December 2019				
				WO	2019228364	A1	05 December 2019				
				CN	110548026	A	10 December 2019				
				TW	202003500	A	16 January 2020				
				WO	2019228363	A1	05 December 2019				
				WO	2019228362	A1	05 December 2019				
				WO	2018030879	A1	15 February 2018	US	2019175583	A1	13 June 2019
								KR	20180018458	A	21 February 2018
JP	2019524808	A	05 September 2019								
US	10792280	B2	06 October 2020								
EP	3498279	A1	19 June 2019								
KR	101934328	B1	02 January 2019								
EP	3498279	A4	29 April 2020								
CN	109640993	A	16 April 2019								
US	2015315176	A1	05 November 2015	ZA	201504601	B	26 October 2016				
				HK	1213262	A1	30 June 2016				
				RU	2015126911	A	31 January 2017				
				BR	112015015229	A2	11 July 2017				
				EP	2938609	A1	04 November 2015				
				CN	105051031	A	11 November 2015				
				ES	2629313	T3	08 August 2017				
				PT	2938609	T	04 July 2017				
				KR	102122569	B1	15 June 2020				
				NZ	709362	A	26 July 2019				
				WO	2014102164	A1	03 July 2014				
				KR	20150100809	A	02 September 2015				
				BR	112015015229	B1	07 July 2020				
				IL	239558	A	31 December 2017				
				BR	112015015229	A8	15 October 2019				
				AU	2013369473	A1	16 July 2015				
				SI	2938609	T1	31 July 2017				
				EP	2938609	B1	12 April 2017				
				LT	2938609	T	26 June 2017				
				DK	2938609	T3	15 May 2017				
				HU	E032621	T2	30 October 2017				
				CA	2896155	A1	03 July 2014				
				SG	11201504951T	A	30 July 2015				
JP	6297590	B2	20 March 2018								
IL	239558	D0	31 August 2015								

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2020/086100

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
				JP	2016503812	A	08 February 2016
				CA	2896155	C	05 May 2020
				CY	1119040	T1	10 January 2018
				AU	2013369473	B2	09 March 2017
				PL	2938609	T3	31 August 2017
				HR	P20170653	T1	30 June 2017
				US	9388168	B2	12 July 2016
				CN	105051031	B	10 October 2017
				RU	2621725	C2	07 June 2017
				SI	EP2938609	T1	31 July 2017
WO	2012006398	A2	12 January 2012	BR	112013000626	B1	26 November 2019
				EP	2590634	A4	13 November 2013
				CN	103153288	A	12 June 2013
				AU	2011276254	B2	03 November 2016
				JP	6042330	B2	14 December 2016
				CN	103153288	B	15 February 2017
				RU	2016125229	A	04 December 2018
				CA	2804926	C	08 January 2019
				RU	2596787	C2	10 September 2016
				ZA	201300877	B	30 April 2014
				KR	20140018832	A	13 February 2014
				PL	2590634	T3	31 October 2016
				IL	224142	A	31 January 2018
				WO	2012006398	A3	05 April 2012
				EP	2590634	B1	09 March 2016
				MX	342120	B	14 September 2016
				AU	2011276254	A1	28 February 2013
				RU	2013105481	A	20 August 2014
				MY	161846	A	15 May 2017
				BR	112013000626	A2	24 May 2016
				JP	2013531036	A	01 August 2013
				CN	107080846	A	22 August 2017
				ES	2575860	T3	01 July 2016
				US	2013209563	A1	15 August 2013
				CA	2804926	A1	12 January 2012
				EP	2590634	A2	15 May 2013
				JP	2016188240	A	04 November 2016
				KR	101942590	B1	25 January 2019
				MX	2013000339	A	11 May 2015
WO	2019228362	A1	05 December 2019	TW	202003502	A	16 January 2020
				TW	202003464	A	16 January 2020
				CN	110548147	A	10 December 2019
				TW	202003499	A	16 January 2020
				CN	110548149	A	10 December 2019
				CN	110548027	A	10 December 2019
				TW	202003501	A	16 January 2020
				CN	110548146	A	10 December 2019
				WO	2019228367	A1	05 December 2019
				WO	2019228366	A1	05 December 2019
				TW	202003498	A	16 January 2020

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2020/086100

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
				CN	110548148	A	10 December 2019
				WO	2019228365	A1	05 December 2019
				WO	2019228364	A1	05 December 2019
				CN	110548026	A	10 December 2019
				TW	202003500	A	16 January 2020
				WO	2019228363	A1	05 December 2019
US	2009264445	A1	22 October 2009	WO	2009127546	A1	22 October 2009
				HR	P20120589	T1	31 August 2012
				CN	102007118	A	06 April 2011
				JP	5518838	B2	11 June 2014
				AU	2009237794	B2	10 July 2014
				KR	20100123912	A	25 November 2010
				CN	102007118	B	31 December 2014
				CA	2720524	A1	22 October 2009
				SI	2274297	T1	31 August 2012
				CY	1112921	T1	13 April 2016
				PT	2274297	E	20 June 2012
				PL	2274297	T3	31 October 2012
				ZA	201006159	B	25 May 2011
				MX	2010011226	A	01 November 2010
				EP	2274297	A1	19 January 2011
				US	7741327	B2	22 June 2010
				BR	PI0911035	A2	16 July 2019
				CL	2009000889	A1	19 July 2010
				JP	2011517692	A	16 June 2011
				AR	071474	A1	23 June 2010
				ES	2386192	T3	13 August 2012
				AU	2009237794	A1	22 October 2009
				KR	101259249	B1	30 April 2013
				RU	2010146384	A	27 May 2012
				IL	207503	A	31 March 2014
				SI	EP2274297	T1	31 August 2012
				TW	200944519	A	01 November 2009
				AT	557017	T	15 May 2012
				IL	207503	D0	30 December 2010
				CA	2720524	C	12 July 2016
				EP	2274297	B1	09 May 2012
				DK	2274297	T3	16 July 2012
				PE	20091842	A1	04 December 2009